Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV-infected patients: Natural history and clinical predictors

Retina

Volumn 22, Issue 3, 2002, Pages 268-277

  Lin, Danny Y ^a   Warren, John F ^b   Lazzeroni, Laura C ^b   Wolitz, Richard A ^b   Mansour, Sam E ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

CD4 count; Cytomegalovirus; Ganciclovir; Highly active antiretroviral therapy; Human immunodeficiency virus; Natural history; Predictor; Protease inhibitor; Remission; Retinitis; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CIDOFOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; FEMALE; HAZARD ASSESSMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PREDICTION; REMISSION; RETINITIS; SURVIVAL; TREATMENT OUTCOME; VIRUS LOAD;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; FEMALE; GANCICLOVIR; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VIRAL LOAD; VIRUS ACTIVATION;

EID: 0036627466     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200206000-00003     Document Type: Article

References (38)

1. Holland GN, et al. Ocular Infection and Immunity. St Louis: Mosby, 1996;1088-1128.
2. Freeman WR, Lerner CW, Mines JA, et al. A prospective study of the ophthalmologic findings in the acquired immunodeficiency syndrome. Am J Ophthalmol 1984;97:133-142.
3. Pertel P, Hirschtick R, Phair J, et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992; 5:1069-1074.
4. Bowen EF, Wilson P, Atkins M, et al. Natural history of untreated cytomegalovirus retinitis. Lancet 1995;346:1671-1673.
5. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-220.
6. Jacobson MA, O'Donnell JJ, Porteous D, et al. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. Qual J Med 1988;67:474-486.
7. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial. 4. visual outcomes. Ophthalmology 1994;101:1250-1261.
8. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-620.
9. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997;337:83-90.
10. Doan S, Chochereau I, Guvenisik N, et al. Cytomegalovirus retinitis in HIV-infected patients with and without highly active antiretroviral therapy. Am J Ophthalmol 1999;128: 250-251.
11. Deayton J, Wilson P, Sabin C, et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 2000;14: 1163-1170.
12. Labetoulle M, Goujard C, Frau E, et al. Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years. J Acquir Immune Defic Syndr 1999;22:228-234.
13. Tural C, Romeu J, Sirera G, et al. Long-last remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998;177:1080-1083.
14. Reed JB, Schwab IR, Gordon J, et al. Regression of cytomegalovirus retinitis associated with protease inhibitor treatment in patients with AIDS. Am J Ophthalmol 1997;124: 199-205.
15. Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevation in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998; 117:1182-1187.
16. Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA 1997;277:1519-1520.
17. Vrabec TR, Baldassano VF, Whitcup SM, et al. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 1998;105:1259-1264.
18. Whitcup SM, Cunningham ETJ, Polis MA, Fortin E. Spontaneous and sustained resolution of CMV retinitis in patients receiving highly active antiretroviral therapy. Br J Ophthalmol 1998;82:845-846.
19. Jabs DA, Bolston SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998;126:817-822.
20. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 1999;282:1633-1637.
21. MacDonald JC, Karavellas MP, Torrianai FJ, et al. Highly active antiretroviral therapy related immune recovery in AIDS patients with cytomegalovirus retinitis. Ophthalmology 2000;107:877-881.
22. Reed JB, Briggs JW, McDonald JC, et al. Highly active antiretroviral therapy-associated regression of cytomegalovirus retinitis: long-term results in a small case series. Retina 2001;21:339-343.
23. Holland GN, Buhles WC, Mastre B, Kaplan HJ, the UCLA CMV Retinopathy Study Group. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Arch Ophthalmol 1989;107:1759-1766.
24. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika 1982;69:553-566.
25. Andersen P, Gill R. Cox's regression model for counting processes, a large sample study. Annals of Statistics 1982; 10:1100-1120.
26. Grambsch P, Therneau T. Proportional hazards test and diagnostics based on weighted residuals. Biometrika 1994;81: 515-526.
27. Van den Horn GJ, Meenken C, Danner SA, et al. Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte responses in HIV+ patients. Br J Ophthalmol 1998;82:988-990.
28. Mitchell SM, Membrey WL, Youle MS, et al. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study. Br J Ophthalmol 1999; 83:652-655.
29. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-1445.
30. Gorochov G, Neumann AU, Kerveur A, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of CD4+ repertoire during antiviral therapy. Nat Med 1998;4:215-221.
31. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
32. Kuppermann BD, Holland GN. Immune recovery uveitis. Am J Ophthalmol 2000;130:103-106.
33. Nguyen QD, Kempen JH, Bolton SG, et al. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 2000;129:634-639.
34. Karavellas MP, Lowder CY, Macdonald C, et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998;116:169-175.
35. Zegans ME, Walton RC, Holland GN, et al. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998;125:292-300.
36. Casado JL, Arrizabalaga J, Montes M, et al. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy: Spanish CMV-AIDS study group. AIDS 1999;13:1497-502.
37. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendation of the international AIDS society-USA panel. JAMA 2000;283:381-390.
38. Miller V. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr 2001;26(suppl 1):S34-50.